Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Alzheimers Dement. 2019 Feb 6;15(5):699–708. doi: 10.1016/j.jalz.2018.12.009

Fig. 4.

Fig. 4.

Proportion of CSF AD biomarker positive individuals in each group by staging method. Cut-offs used to determine biomarker positivity [21]: <977 pg/ml for Aβ1-42, >.025 for pTau/ Aβ1-42, and >.27 for tTau/Aβ1-42.